Article

EGFR Activation Increases Parathyroid Hyperplasia and Calcitriol Resistance in Kidney Disease

Renal Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Journal of the American Society of Nephrology (Impact Factor: 9.34). 03/2008; 19(2):310-20. DOI: 10.1681/ASN.2007040406
Source: PubMed

ABSTRACT

Calcitriol, acting through vitamin D receptors (VDR) in the parathyroid, suppresses parathyroid hormone synthesis and cell proliferation. In secondary hyperparathyroidism (SH), VDR content is reduced as hyperplasia becomes more severe, limiting the efficacy of calcitriol. In a rat model of SH, activation of the EGF receptor (EGFR) by TGF-alpha is required for the development of parathyroid hyperplasia, but the relationship between EGFR activation and reduced VDR content is unknown. With the use of the same rat model, it was found that pharmacologic inhibition of EGFR activation with erlotinib prevented the upregulation of parathyroid TGF-alpha, the progression of growth, and the reduction of VDR. Increased TGF-alpha/EGFR activation induced the synthesis of liver-enriched inhibitory protein, a potent mitogen and the dominant negative isoform of the transcription factor CCAAT enhancer binding protein-beta, in human hyperplastic parathyroid glands and in the human epidermoid carcinoma cell line A431, which mimics hyperplastic parathyroid cells. Increases in liver-enriched inhibitory protein directly correlated with proliferating activity and, in A431 cells, reduced VDR expression by antagonizing CCAAT enhancer binding protein-beta transactivation of the VDR gene. Similarly, in nodular hyperplasia, which is the most severe form of SH and the most resistant to calcitriol therapy, higher TGF-alpha activation of the EGFR was associated with an 80% reduction in VDR mRNA levels. Thus, in SH, EGFR activation is the cause of both hyperplastic growth and VDR reduction and therefore influences the efficacy of therapy with calcitriol.

Download full-text

Full-text

Available from: Ignacio González-Suárez, Jul 23, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Affinity alkylating derivatives of naturally occurring molecules were originally developed to target and probe the substrate/ligand-binding sites of enzymes and receptors. These reagents, by virtue of their ability to covalently attach to the substrate/ligand-binding pockets of target enzymes/receptors, provide valuable structural information of the host and the guest, focusing on the dynamic interaction between the two. Our laboratory developed affinity and photoaffinity labeling derivatives of 1,25-dihydroxyvitamin D3 [1,25(OH)2D] to probe the ligand-binding domain of nuclear vitamin D receptor (VDR). With these studies we obtained crucial information about the ligand contact points and three-dimensional geometry of the ligand-binding domain of VDR, in relation to the biological properties of 1,25(OH)2D. 1,25(OH)2D is an anticancer agent, albeit with severe toxicity at pharmacological doses. We observed that an affinity alkylating derivative of 1,25(OH)2D strongly inhibits the growth of various cancer cells and causes these cells to undergo apoptosis, demonstrating strong potential of this affinity analog of 1,25(OH)2D as an anticancer agent. This article summarizes the results of various studies involving affinity alkylating derivatives of vitamin D metabolites to investigate structural–functional aspects of VDR, as well as development of these reagents as potential therapeutic agents in cancer.
    No preview · Article ·
  • [Show abstract] [Hide abstract]
    ABSTRACT: A solution growth process is employed for the deposition of CdS1 − xSex thin film composites with 0 ≤x≤ 1. Cadmium acetate, thiourea and sodium selenosulphate were used as the basic source materials. The samples were obtained at 55 °C in an alkaline medium and were characterised by optical and electrical characterisation techniques. The layer thickness is found to be decreased as x is varied from 0 to 1. The optical absorption studies showed a high coefficient of absorption (α = 104 cm−1) with an allowed direct type of transition. The optical energy gap decreases continuously (typically from 2.42 eV to 1.74 eV) as x is increased from 0 to 1. For values of x between 0.5 and 0.8, two absorption edges have been observed; one at approximately 2.40 eV corresponding to the fundamental optical transitions in CdS and the other decreasing continuously, which corresponds to the fundamental transitions in CdS1 − xSex solid solution. The electrical conductivity is found to decrease up to x = 0.5 and to increase thereafter for further increase in x. The activation energy is more or less the same for all compositions and has no systematic dependence on the composition parameter x.
    No preview · Article · Feb 1997 · Materials Chemistry and Physics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Secondary hyperparathyroidism is characterised by excessive secretion of parathyroid hormone and parathyroid hyperplasia, resulting in both skeletal and extraskeletal consequences. Recent basic and clinical studies have brought considerable advances in our understanding of the pathophysiology of parathyroid hyperplasia and have also provided practical therapeutic approaches, especially with regard to indications for parathyroid intervention. In this context, it is quite important to recognize the development of nodular hyperplasia, because the cells in nodular hyperplasia are usually resistant to calcitriol treatment. Patients with nodular hyperplasia should undergo parathyroid intervention including percutaneous ethanol injection therapy (PEIT). Selective PEIT of the parathyroid gland is an effective approach in which the enlarged parathyroid gland with nodular hyperplasia is ‘selectively’ destroyed by ethanol injection, and other glands with diffuse hyperplasia are then managed by medical therapy. With a more focused attention to applying parathyroid intervention, we can expect significant improvement in the management of secondary hyperparathyroidism in dialysis patients.
    Full-text · Article · Aug 2008 · NDT Plus
Show more